key: cord-0759011-rkgrsiqf authors: Bacher, Petra; Rosati, Elisa; Esser, Daniela; Martini, Gabriela Rios; Saggau, Carina; Schiminsky, Esther; Dargvainiene, Justina; Schöder, Ina; Wieters, Imke; Khodamoradi, Yascha; Eberhardt, Fabian; Vehreschild, Maria J.G.T.; Neb, Holger; Sonntagbauer, Michael; Conrad, Claudio; Tran, Florian; Rosenstiel, Philip; Markewitz, Robert; Wandinger, Klaus-Peter; Augustin, Max; Rybniker, Jan; Kochanek, Matthias; Leypoldt, Frank; Cornely, Oliver A.; Koehler, Philipp; Franke, Andre; Scheffold, Alexander title: Low avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19 date: 2020-11-26 journal: Immunity DOI: 10.1016/j.immuni.2020.11.016 sha: 7ed04483e301a64145eb70b9a4409d77e88a5b31 doc_id: 759011 cord_uid: rkgrsiqf CD4+ T cells reactive against SARS-CoV-2 can be found in unexposed individuals and these are suggested to arise in response to common cold corona viruses (CCCoVs) infection. Here, we utilized SARS-CoV-2-reactive CD4+ T cell enrichment to examine the antigen-avidity and clonality of these cells, as well as the relative contribution of CCCoV cross-reactivity. SARS-CoV-2-reactive CD4+ memory T-cells were present in virtually all unexposed individuals examined, displaying low functional avidity and multiple, highly variable cross-reactivities that were not restricted to CCCoVs. SARS-CoV-2 reactive CD4+ T cells from COVID-19 patients lacked cross-reactivity to CCCoVs, irrespective of strong memory T-cell responses against CCCoV in all donors analysed. In severe but not mild COVID-19, SARS-CoV-2-specific T-cells displayed low functional avidity and clonality, despite increased frequencies. Our findings identify low avidity CD4+T cell responses as a hallmark of severe COVID-19, and argue against a protective role for CCCoV reactive T cells in SARS-CoV-2 infection. COVID-19 displays remarkable disparity of clinical symptoms, ranging from asymptomatic or 57 mild disease frequently observed in children and younger adults to severe clinical symptoms 58 associated with high mortality mainly in elderly and high-risk patients. These different 59 pathologies are likely to be the result of differences in the immune response to SARS-CoV-2. Several studies show that a significant fraction of un-exposed donors possess SARS-CoV-2- donors was verified by SARS-CoV-2 PCR and/ or serology testing (Table S1 , S2). The response of COVID-19 patients was mainly directed against three proteins, spike, 123 membrane and nucleocapsid, as previously reported , as well as to lower 124 extent and with more variability between donors against ORF3a, ORF9b, NS6, NS7a and 125 NS8 ( Figure 1A UMAP cluster analysis revealed five clusters with a distinct transcriptional profile (Figure 2A ). These were assigned as T follicular-helper-like (Tfh-like, key marker genes IL21, POU2AF1), 7 ( Figure 2B ). Similar clusters have recently been described in SARS-CoV-2-specific T cells 150 (Meckiff et al., 2020) . Especially Tfh-like, transitional and central memory T cells showed a 151 related profile with variable gene expression of IFNG, CSF2, IL21, IL2 and PDCD1 (Figures 152 2B, Figure S2A , B). We also observed three robust clusters (cytotoxic /Th1, type-I interferon, 153 and cycling) indicative of cellular activation and an anti-viral type-I interferon response. Similar clusters were also identified in SARS-CoV-2 reactive memory T cells from unexposed 155 individuals and we were not able to clearly separate unexposed donors from COVID-19 156 patients or between patients with different disease severity only based on qualitative 157 differences of the reactive T cells ( Figure 2C , Figure S2B ). Increased expression of the acute and chronic activation markers Ki-67 and CD38, was 159 confirmed by flow-cytometry ( Figure 2D , Figure S3A ) and declined with time after infection 160 ( Figure 2E ), in contrast to the frequencies of reactive T cells ( Figure S3B ). Relative, but 161 especially absolute levels of inflammatory cytokines were increased in COVID-19, such as 162 IL-2, IFN-γ and IL-21, compared to unexposed individuals ( Figure S3C ,D). We also observed 163 a slightly higher production of IL-10. While inflammatory cytokines increased with time after 164 infection, IL-10 was mainly produced during active disease ( Figure S3E ). This finding 165 suggests a counter-regulatory mechanism during acute infection. We observed no 166 differences in the cytokine response or phenotype between the individual SARS-CoV-2 167 proteins ( Figure S4 ). Taken together, COVID-19 patients generated a pro-inflammatory Th1/cytotoxic-like and Tfh-169 like response against SARS-CoV-2 spike, membrane, and nucleocapsid proteins. However, 170 the differences between patients and unexposed individuals were mainly quantitative rather 171 than qualitative. This suggests that the identified cell clusters are not unique to COVID-19 but 172 may represent a common cellular phenotype of anti-viral T cells. Recent studies show pre-existing T cell immunity against SARS-CoV-2 in 20-81% of Variable cross-reactivity is reported against homologuous epitopes from common cold In summary, these data show that antigen-reactive T cells against newly encountered 214 antigens, such as SARS-CoV-2 are present within a natural memory T cell repertoire, most 215 likely due to TCR intrinsic cross-reactivity, as previously described (Bacher et CCCoV spike-reactive T cells showed higher production of the inflammatory cytokines IFN-γ, TNF-α, IL-2 and IL-21 compared to SARS-CoV-2 spike-reactive T cells from unexposed 235 individuals ( Figure 4G , H, Figure S4 ). In summary, these data show that robust memory CD4+ T cell responses to all four common We next compared the response quality of patients with mild (non-hospitalized) versus 274 severe (hospitalized) disease. Classification was based on WHO criteria, whereby WHO 275 groups 3-5 (moderate) and 6-7 (severe) were combined to increase statistical power (see 276 Table S1 ). We found higher frequencies of reactive T cells against the single and pooled 277 SARS-CoV-2 proteins with increasing disease severity ( Figure 6A ). No such correlation was 278 observed for Influenza A as control antigen. The increased frequencies in severe disease 279 were not due to an age bias as shown for a selected group of donors in the age range of 50-280 65 years ( Figure 6B , C, Figure S7 ). However, hospitalized versus non-hospitalized patients 281 within the same age group showed an increased proportion of memory cells within the CD4+ T cell compartment ( Figure 6D ). We next compared TCR avidities and clonalities of SARS- Figure 6I ). This was not significant due to one outlier (grey dot in Figure 6G In summary, our data reveal that severe COVID-19 patients showed a strong but rather 303 unfocused CD4+ T cell response. This was characterized by low avidity T cells originating 304 from a rather polyclonal repertoire. Severe disease was also associated with an enlarged 305 total CD4+ memory compartment. However, we do not know the patients pre-infection status We found that patients with severe COVID-19 harbored low avidity CD4+ T cells, which were based on WHO criteria, whereby WHO groups 3-5 (moderate) and 6-7 (severe) were 639 combined to increase statistical power (see Table S1 ). Unexposed donors n=50, non- Table S1 and S2 for further details). 51 of 56 COVID-19 patients were tested containing more than 1 TCR alpha and 1 TCR beta (ii) containing more than 1 TCR alpha 806 and no TCR beta sequence (iii) containing more than 1 TCR beta and no TCR alpha 807 sequence (iv) containing more than 2 TCR alpha or more than 2 TCR beta sequences. Alpha diversity measures were calculated for each patient either for the whole repertoire or 809 divided based on Seurat clusters. R packages "vegan" and "tcR" were used to calculate the Bacher et al. identify excessive but low avidity T cell responses to SARS-CoV-2 as a hallmark of severe but not mild COVID-19. Pre-existing memory to SARS-CoV-2 in unexposed donors also displayed low avidity and harbored multiple, highly variable crossreactivities that were not restricted to common cold coronaviruses. COVID-19 progression is potentially 860 driven by T cell immunopathogenesis. medRxiv Regulatory T Cell Specificity Directs Tolerance versus 863 Allergy against Aeroantigens in Humans Human Anti-fungal Th17 Immunity and 866 Pathology Rely on Cross-Reactivity against Candida albicans Flow-cytometric analysis of rare antigen-specific T cells New technologies for monitoring human antigen-870 specific T cells and regulatory T cells by flow-cytometry Antigen-reactive T cell enrichment for direct, high-resolution analysis of 873 the human naive and memory Th cell repertoire Deconstructing the peptide-MHC 876 specificity of T cell recognition SARS-CoV-2-reactive T cells in healthy donors Targets of T Cell Responses to 908 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Natural T Cell-mediated 912 Protection against Seasonal and Pandemic Influenza Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 916 Lancet Fast, sensitive and accurate integration of single-919 cell data with Harmony Human CD8(+) T cell cross-reactivity 922 across influenza A, B and C viruses Frequency of epitope-specific naive CD4(+) T cells correlates with 925 immunodominance in the human memory repertoire Virtual memory cells 927 make a major contribution to the response of aged influenza-naive mice to influenza virus 928 infection Impact of ageing on 930 the response and repertoire of influenza virus-specific CD4 T cells SARS-CoV-2-specific T cell immunity in cases of COVID-933 19 and SARS, and uninfected controls Selective and cross-reactive SARS-CoV-2 T cell 936 epitopes in unexposed humans Imbalance of regulatory and cytotoxic 939 SARS-CoV-2-reactive CD4+ T cells in COVID-19. Cell SARS-CoV-2-derived peptides define heterologous and 942 COVID-19-induced T cell recognition Broad and strong memory CD4(+) and CD8(+) T cells induced by 945 SARS-CoV-2 in UK convalescent individuals following COVID-19 Antigen-Specific Adaptive Immunity 948 to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity Low Thymic Activity and Dendritic Cell Numbers 952 Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans Robust T Cell Immunity in 956 Convalescent Individuals with Asymptomatic or Mild COVID-19 Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 958 infection. medRxiv Pre-existing immunity to SARS-CoV-2: the knowns and 960 unknowns Why must T cells be cross-reactive? Cellular immune correlates of protection 964 against symptomatic pandemic influenza Genesis: cluster analysis of microarray 966 data Virus-specific CD4(+) 968 memory-phenotype T cells are abundant in unexposed adults Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-974 Infected Pneumonia in Phenotype 977 and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory 978 distress syndrome Heterologous immunity between 980 viruses A single-cell atlas of the peripheral 983 immune response in patients with severe COVID-19 Immunity and age: living in the past? Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, 988 China: a single-centered, retrospective, observational study Elevated exhaustion levels and reduced functional diversity of T cells in 991 peripheral blood may predict severe progression in COVID-19 patients